Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JAMP Pharma Corporation

Latest From JAMP Pharma Corporation

Alvotech And Jamp Launch First Stelara Biosimilar In Canada

Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.

Biosimilars Launches

Alvotech Notches Up Another Stelara Biosimilar Approval – In Canada

Alvotech and local partner Jamp Pharma have received the first Canadian approval for an ustekinumab biosimilar rival to Stelara in the form of Jamteki, with Health Canada’s marketing authorization following earlier nods for Alvotech’s AVT04 candidate in other geographies.

Approvals Biosimilars

Jamp To Offer Canadian Sitagliptin, Sandoz Bags Fixed-Dose Combo

An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.

Approvals Launches

Alvotech Achieves Japan Milestone, Expands In Canada

Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.

Biosimilars Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs